DALLAS / Apr 20, 2023 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced it will report its results for the first quarter ended March 31, 2023, on May 9, 2023, and host a webcast and conference call on May 10, 2023. Individuals who would like to participate in the conference call webcast should join 15 minutes before the scheduled start time.
A link to the webcast of the conference call and online replay can be found on Enhabit’s investor website at the web address provided above.
About Enhabit Home Health & Hospice
Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 253 home health locations and 107 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.
| Last Trade: | US$8.11 |
| Daily Change: | 0.05 0.62 |
| Daily Volume: | 380,795 |
| Market Cap: | US$411.100M |
August 06, 2025 May 07, 2025 November 06, 2024 August 06, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
